Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Lymphoma Clinical Trial

Official title:

A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01273090
• Other study ID #: ADVL1112
• Secondary ID: COG-ADVL1112
• Status: Completed
• Phase: Phase 1
• First received: January 7, 2011
• Last updated: January 29, 2014
• Start date: May 2011
• Est. completion date: October 2013

Study information

• Verified date: January 2014
• Source: Children's Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in treating young patients with refractory or recurrent solid tumors or lymphoma.

Description:

OBJECTIVES:

Primary

• To estimate the maximum-tolerated dose (MTD) and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma.

• To define and describe the toxicities of imetelstat sodium.

• To characterize the pharmacokinetics of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma.

Secondary

• To determine, in a preliminary manner, the antitumor effects of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma. (exploratory)

• To provide preliminary assessment of the biological activity of imetelstat sodium in children with recurrent or refractory malignancies by assessing telomerase activity, telomere length, hTERT protein, hTERT mRNA, and hTR levels in patient peripheral blood mononuclear cells (PBMNC) samples pretreatment and on treatment. (Exploratory)

• To assess telomerase activity, hTERT expression, telomere length, hTERT protein, hTERT mRNA, and hTR levels in patients' pretreatment tumor samples. (Exploratory)

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection at baseline and periodically during study for pharmacokinetic and correlative studies. Tumor tissue samples from diagnosis and/or subsequent tumor resections or biopsies may also be collected for correlative studies.

After completion of study therapy, patients are followed up for 30 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: October 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 21 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of refractory or recurrent solid tumors, including lymphoma

• No CNS tumors or known CNS metastases (Part A, dose escalation)

• CNS tumors or known CNS metastases allowed (Part B, maximum-tolerated dose or recommended phase II dose)

• No prior or concurrent CNS hemorrhage on a baseline MRI within the past 14 days

• All patients must have histologic verification of malignancy at original diagnosis or relapse except for:

• Intrinsic brain stem tumors

• Optic pathway gliomas

• Pineal tumors and elevations of CSF or serum tumor markers including alpha-fetoprotein or beta-HCG

• Measurable or evaluable disease

• Disease for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life

• Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood count criteria and they are not known to be refractory to red cell or platelet transfusions

PATIENT CHARACTERISTICS:

• Karnofsky performance status (PS) 50-100% (patients > 16 years of age) OR Lansky PS 50-100% (patients = 16 years of age)

• ANC = 1,000/mm³

• Platelet count = 100,000/mm³ (transfusion-independent, defined as not receiving platelet transfusion within the past 7 days prior to enrollment)

• Creatinine clearance or radioisotope GFR = 70 mL/min OR a serum creatinine based on age and/or gender as follows:

• 0.6 mg/dL (1 to < 2 years of age)

• 0.8 mg/dL (2 to < 6 years of age)

• 1.0 mg/dL (6 to < 10 years of age)

• 1.2 mg/dL (10 to < 13 years of age)

• 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age)

• 1.7 mg/dL (male) or 1.4 mg/dL (female) (= 16 years of age)

• Bilirubin (sum of conjugated and unconjugated) = 1.5 times upper limit of normal (ULN)

• ALT = 110 U/L (ULN for ALT is 45 U/L)

• Serum albumin = 2 g/dL

• aPTT < 1.2 times ULN

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use an effective contraception method

• No uncontrolled infection

• No patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

PRIOR CONCURRENT THERAPY:

• Recovered from acute toxic effects of all prior anti-cancer chemotherapy, immunotherapy, or radiotherapy

• At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)

• At least 14 days since prior long-acting growth factor (e.g., Neulasta) or = 7 days since prior short-acting growth factor

• At least 7 days since prior biologic or anti-neoplastic agent

• At least 6 weeks since any type of prior immunotherapy (e.g., tumor vaccines)

• At least 3 half-lives since last dose of a monoclonal antibody

• At least 2 weeks since prior local palliative radiotherapy (small port)

• At least 24 weeks since prior total-body irradiation, craniospinal radiotherapy, or radiation to = 50% of the pelvis

• At least 6 weeks since prior substantial bone marrow radiation

• At least 12 weeks since prior transplantation or stem cell infusion with no evidence of active graft vs host disease

• Prior and concurrent stable or decreasing dose of corticosteroids within the past 7 days allowed

• No prior allogeneic transplant

• No other concurrent investigational drug

• No other concurrent anticancer agents including chemotherapy, radiotherapy, immunotherapy, or biologic therapy

• No concurrent cyclosporine, tacrolimus, or other agents to prevent either graft-versus-host disease post-bone marrow transplant or organ rejection post-transplant

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Brain and Central Nervous System Tumors
• Central Nervous System Neoplasms
• Lymphoma
• Lymphoproliferative Disorder
• Lymphoproliferative Disorders
• Neoplasms
• Nervous System Neoplasms
• Small Intestine Cancer
• Unspecified Childhood Solid Tumor, Protocol Specific

Intervention

Drug:
• imetelstat sodium

Other:
• laboratory biomarker analysis

• pharmacological study

Locations

Country	Name	City	State
Canada	Hopital Sainte Justine	Montreal	Quebec
Canada	Hospital for Sick Children	Toronto	Ontario
United States	C.S. Mott Children's Hospital at University of Michigan Medical Center	Ann Arbor	Michigan
United States	AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus	Atlanta	Georgia
United States	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office	Bethesda	Maryland
United States	UAB Comprehensive Cancer Center	Birmingham	Alabama
United States	Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Children's Memorial Hospital - Chicago	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas	Dallas	Texas
United States	Baylor University Medical Center - Houston	Houston	Texas
United States	Riley's Children Cancer Center at Riley Hospital for Children	Indianapolis	Indiana
United States	St. Jude Children's Research Hospital	Memphis	Tennessee
United States	Midwest Children's Cancer Center at Children's Hospital of Wisconsin	Milwaukee	Wisconsin
United States	Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center	New York	New York
United States	Children's Hospital of Orange County	Orange	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Children's Hospital of Pittsburgh of UPMC	Pittsburgh	Pennsylvania
United States	Knight Cancer Institute at Oregon Health and Science University	Portland	Oregon
United States	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California
United States	Children's Hospital and Regional Medical Center - Seattle	Seattle	Washington
United States	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis	St. Louis	Missouri
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Children's Oncology Group	National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum-tolerated dose and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma		21 Days	Yes
Primary	Toxicities of imetelstat sodium		Up to 30 days post-treatment	Yes